Medtronic (NYSE:MDT) today shared real-world evidence highlighting improvements with its MiniMed 780G automated insulin delivery system.
MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.
Our sister site, Drug Delivery Business News, reports that data demonstrated rapid, sustained improvements in glycemic control for people living with type 1 diabetes. It also showed the significant reduction in patient burden by automating a growing percentage of insulin delivery over time.
Investigators presented findings at the European Association for the Study of Diabetes (EASD) 61st Annual Meeting in Vienna. The milestones come not long after recent FDA approvals for MiniMed 780G, highlighting the system’s capabilities ahead of the company’s planned separation of the Diabetes unit into a standalone, publicly traded company.
Get the full story at our sister site, Drug Delivery Business News.
